Inhibitory effects of Rhenium-188-labeled Herceptin on prostate cancer cell growth: A possible radioimmunotherapy to prostate carcinoma

International Journal of Radiation Biology

Volumn 89, Issue 5, 2013, Pages 346-355

  Wang, Hsin Yi ^a,b   Lin, Wan Yu ^b   Chen, Mei Chih ^a   Lin, Teh ^f   Chao, Chih Hao ^c   Hsu, Fu Ning ^a   Lin, Eugene ^a,c   Huang, Chih Yang ^d,h   Luo, Tsai Yueh ^e   Lin, Ho ^a,d,g  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHANG BING SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h ASIA UNIVERSITY   (Taiwan)

Author keywords

Cdk5; Her2; Herceptin; Prostate cancer; Rhenium 188

Indexed keywords

HERCEPTIN RE 188; PROTEIN P35; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOTHERAPY; TISSUE SPECIFICITY; TUMOR XENOGRAFT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 5; HUMANS; ISOTOPE LABELING; MALE; MICE; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RHENIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877272202     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2013.762136     Document Type: Article

References (39)

1. Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW . 1999. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models . Cancer Research 59: 4761- 4764
2. Ahmad I, Patel R, Singh LB, Nixon C, Seywright M, Barnetson RJ, Brunton VG, Muller WJ, Edwards J, Sansom OJ, Leung HY . 2011 HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer . Proceedings of the National Academy of Sciences of the USA 108 : 16392 - 16397
3. Albanell J, Codony J, Rovira A, Mellado B, Gascon P . 2003 . Mechanism of action of anti-HER2 monoclonal antibodies: Scientifi c update on trastuzumab and 2C4 . Advances in Experimental Medicine and Biology 532 : 253 - 268
4. Bolin C, Boudra MT, Fernet M, Vaslin L, Pennaneach V, Zaremba T, Biard D, Cordelieres FP, Favaudon V, Megnin-Chanet F, Hall J . 2012 . The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation . Cellular and Molecular Life Sciences 69 : 951 - 962
5. Calvo BF, Levine AM, Marcos M, Collins QF, Iacocca MV, Caskey LS, Gregory CW, Lin Y, Whang YE, Earp HS, Mohler JL . 2003 . Human epidermal receptor-2 expression in prostate cancer . Clinical Cancer Research 9: 1087- 1097
6. Chen KT, Lee TW, Lo JM . 2009. In vivo examination of (188)Re(I)- tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer . Nuclear Medicine and Biology 36 : 355 - 361
7. Demelash A, Rudrabhatla P, Pant HC, Wang X, Amin ND, McWhite CD, Naizhen X, Linnoila RI . 2012 . Achaete-Scute Homolog-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway . Molecular Biology of the Cell 23 : 2856-2866
8. Dhavan R, Tsai LH . 2001. A decade of CDK5. Nature Reviews Molecular Cell Biology 2 : 749 - 759
9. Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI . 1994 . The neu-oncogene: Signal transduction pathways, transformation mechanisms and evolving therapies . Oncogene 9: 2109- 2123
10. Eggers JP, Grandgenett PM, Collisson EC, Lewallen ME, Tremayne J, Singh PK, Swanson BJ, Andersen JM, Caff rey TC, High RR, Ouellette M, Hollingsworth MA . 2011. Cyclin-dependent kinase 5 is amplifi ed and overexpressed in pancreatic cancer and activated by mutant K-Ras . Clinical Cancer Research 17: 6140- 6150
11. Formento P, Hannoun-Levi JM, Gerard F, Mazeau C, Fischel JL, Etienne-Grimaldi MC, Gugenheim J, Milano G . 2005 . Gefi tinibtrastuzumab combination on hormone-refractory prostate cancer xenograft . European Journal of Cancer 41 : 1467 - 1473
12. Henry RY, O ' Mahony D . 1999 . Treatment of prostate cancer . Journal of Clinical Pharmacy and Therapeutics 24: 93- 102
13. Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM . 2004 . Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence . British Journal of Cancer 90 : 449 - 454
14. Hsu FN, Yang MS, Lin E, Tseng CF, Lin H . 2011a . The signifi cance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells . American Journal of Physiology, Endocrinology and Metabolism 300: E902- 908
15. Hsu FN, Chen MC, Chiang MC, Lin E, Lee YT, Huang PH, Lee GS, Lin H . 2011b . Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5 . Journal of Biological Chemistry 286 : 33141 - 33149
16. Jemal A, Siegel R, Ward E, Murray T, Xu J, Th un MJ . 2007. Cancer statistics, 2007. CA: A Cancer Journal for Clinicians 57 : 43 - 66
17. Lee KY, Rosales JL, Tang D, Wang JH . 1996. Interaction of cyclindependent kinase 5 (Cdk5) and neuronal Cdk5 activator in bovine brain . Journal of Biological Chemistry 271 : 1538 - 1543
18. Legrier ME, Oudard S, Judde JG, Guyader C, de Pinieux G, Boye K, de Cremoux P, Dutrillaux B, Poupon MF . 2007 . Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms . British Journal of Cancer 96 : 269 - 276
19. Lin H, Juang JL, Wang PS . 2004. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis . Journal of Biological Chemistry 279 : 29302 - 29307
20. Lin H, Lin TY, Juang JL . 2007a . Abl deregulates Cdk5 kinase activity and subcellular localization in Drosophila neurodegeneration . Cell Death and Differentiation 14 : 607 - 615
21. Lin H, Chen MC, Chiu CY, Song YM, Lin SY . 2007b . Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells . Journal of Biological Chemistry 282 : 2776 - 2784
22. Luo TY, Tang IC, Wu YL, Hsu KL, Liu SW, Kung HC, Lai PS, Lin WJ . 2009 . Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment . Nuclear Medicine and Biology 36 : 81 - 88
23. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL . 2004 . HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability . Cancer Cell 6 : 517 - 527
24. Meyn RE . 1997 . Apoptosis and response to radiation: Implications for radiation therapy. Oncology (Williston Park) 11: 349- 356; discussion 356,361,365
25. Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI . 2002 . HER-2 profi ling and targeting in prostate carcinoma . Cancer 94: 980- 986
26. Neve RM, Lane HA, Hynes NE . 2001 . The role of overexpressed HER2 in transformation . Annals of Oncology 12: S9 - 13
27. Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, Ross JS, Cordon-Cardo C . 2001 . HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer . Clinical Cancer Research 7: 2643- 2647
28. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH . 1999 . Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration . Nature 402 : 615 - 622
29. Rasaneh S, Rajabi H, Babaei MH, Daha FJ . 2010. 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer . Nuclear Medicine and Biology 37 : 949 - 955
30. Sgambato A, Camerini A, Faraglia B, Ardito R, Bianchino G, Spada D, Boninsegna A, Valentini V, Cittadini A . 2004 . Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 (' Iressa ') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells . Journal of Cellular Physiology 201 : 97 - 105
31. Sharkey RM, Goldenberg DM . 2011. Cancer radioimmunotherapy Immunotherapy 3: 349- 370
32. Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, Lieskovsky G, Cote RJ . 2001. Her-2/neu expression in prostate cancer: High level of expression associated wiThexposure to hormone therapy and androgen independent disease . Journal of Urology 166 : 1514 - 1519
33. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Th omas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M . 2000 . Her-2-neu expression and progression toward androgen independence in human prostate cancer . Journal of the National Cancer Institute 92 : 1918 - 1925
34. Stavridi F, Karapanagiotou EM, Syrigos KN . 2010. Targeted therapeutic approaches for hormone-refractory prostate cancer . Cancer Treatment Reviews 36: 122- 130
35. Stephens LC, Ang KK, Schultheiss TE, Milas L, Meyn RE . 1991. Apoptosis in irradiated murine tumors . Radiation Research 127: 308- 316
36. Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, Nelkin BD . 2006 . Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells . Cancer Research 66 : 7509 - 7515
37. Telliez A, Desroses M, Pommery N, Briand O, Farce A, Laconde G, Lemoine A, Depreux P, Henichart JP . 2007. Derivatives of Iressa, a specifi c epidermal growth factor receptor inhibitor, are powerful apoptosis inducers in PC3 prostatic cancer cells . ChemMedChem 2 : 318 - 332
38. Tsai LH, Delalle I, Caviness VS Jr, Chae T, Harlow E . 1994. p35 is a neural-specifi c regulatory subunit of cyclin-dependent kinase 5 . Nature 371 : 419 - 423
39. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED . 2004. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60: 332- 337